Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?

Anti-Cancer Drugs

Volumn 23, Issue 6, 2012, Pages 579-583

  Morris, Patrick G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

bevacizumab; biomarkers; glioblastoma; high grade glioma; irinotecan; phase II trials; quality of life; randomized phase III trial; response assessment

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; IMATINIB; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN; VEMURAFENIB; ANTINEOPLASTIC AGENT;

BLEEDING; BRAIN HEMORRHAGE; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL (TOPIC); COLON CANCER; DIARRHEA; DRUG FATALITY; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; GLIOMA; HUMAN; INTESTINE PERFORATION; LUNG CANCER; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SINGLE DRUG DOSE; TUMOR BLEEDING; TUMOR RESISTANCE; TUMOR VOLUME; UNITED STATES; VENOUS THROMBOEMBOLISM; CENTRAL NERVOUS SYSTEM NEOPLASMS; MORTALITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOMA; HUMANS;

EID: 84861819039     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283528847     Document Type: Review

References (28)

1. Morris PG, Lassman AB. Medical oncology: optimizing chemotherapy and radiotherapy for anaplastic glioma. Nat Rev Clin Oncol 2010; 7: 428-430.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
3. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003; 62:297-303.
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel\carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
7. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255-5261.
8. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-4729.
9. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
11. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010; 15:1329-1334.
12. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
13. Gil MJ, de las Peñas R, Reynesc G, Balañád C, Perez-Segurae P, Garćia-Velascof A, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs 2012; (in press).
14. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
16. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345:1008-1012.
17. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17:1516-1525.
18. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003; 97:2381-2386.
19. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006; 8:189-193.
20. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002; 56:183-188.
21. Lemasson B, Serduc R, Maisin C, Bouchet A, Coquery N, Robert P, et al. Monitoring blood\brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology 2010; 257:342-352.
22. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009; 72:1217-1222.
23. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377:914-923.
24. Morris PG. Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs 2010; 21:885-889
25. Temozolomide with or without bevacizumab in treating patients with recurrent glioma. Available at www.clinicaltrials.gov/show/NCT01164189 [Accessed 30 January 2012]
26. Bevacizumab and lomustine in treating patients with glioblastoma multiforme in first recurrence. Available at www.clinicaltrials.gov/show/ NCT01290939 [Accessed 30 January 2012].
27. Standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) for recurrent glioblastoma multiforme (GBM). Available at www.clinicaltrials.gov/show/NCT01067469 [Accessed 30 January 2012].
28. Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma. Availabe at www.clinicaltrials. gov/show/NCT00884741 [Accessed 30 January 2012].